These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9169812)

  • 1. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Jiroutek M; Malkowicz SB; Wein A; Coleman CN
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1053-8. PubMed ID: 9169812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Wein A; Tomaszewski JE; Coleman CN
    Cancer; 1998 Jan; 82(2):334-41. PubMed ID: 9445191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV.
    D'Amico AV; Whittington R; Kaplan I; Beard C; Schultz D; Malkowicz SB; Tomaszewski JE; Wein A; Coleman CN
    Int J Radiat Oncol Biol Phys; 1997 Sep; 39(2):335-40. PubMed ID: 9308936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation.
    Stokes SH
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):129-36. PubMed ID: 10758314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution.
    Martinez AA; Gonzalez JA; Chung AK; Kestin LL; Balasubramaniam M; Diokno AC; Ziaja EL; Brabbins DS; Vicini FA
    Cancer; 2000 Jan; 88(2):425-32. PubMed ID: 10640977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
    Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer.
    Beard CJ; Chen MH; Cote K; Loffredo M; Renshaw AA; Hurwitz M; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):19-24. PubMed ID: 14697416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Fondurulia J; Chen MH; Kaplan I; Beard CJ; Tomaszewski JE; Renshaw AA; Wein A; Coleman CN
    J Clin Oncol; 1999 Jan; 17(1):168-72. PubMed ID: 10458230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the biopsy Gleason score on PSA outcome for prostate cancer patients with PSA < or = 10 ng/ml and T1c,2a: implications for patient selection for prostate-only therapy.
    D'Amico AV; Renshaw AA; Schultz D; Rocha S; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):847-51. PubMed ID: 10571188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.
    D'Amico AV; Renshaw AA; Arsenault L; Schultz D; Richie JP
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):841-6. PubMed ID: 10571187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group.
    Lattanzi JP; Hanlon AL; Hanks GE
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):569-73. PubMed ID: 9231681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.